Viking Therapeutics is a clinical-stage biotech company focused on developing weight-loss therapies. Read why I rate VKTX ...

And with a growing number of companies in the GLP-1 space, investors may be losing interest in the stock. Could Viking's ...

Viking thinks the oral alternative offers a smooth transition from the subcutaneous form and might appeal to individuals reluctant about injectable therapies. The business completed an End-of-Phase 2 ...

San Diegan biotech Viking Therapeutics (Nasdaq: VKTX) has announced plans to initiate late-stage clinical trials for its ...

Viking Therapeutics announces its fourth-quarter financial results after Wednesday's closing bell. Here's a look at the ...

Raymond James analyst Steven Seedhouse raised the firm’s price target on Viking Therapeutics (VKTX) to $125 from $122 and keeps a Strong Buy ...

One of the hottest growth areas in the healthcare landscape these days is the obesity drug market because of a class of drugs that's proven to be both efficacious and safe in clinical studies and in ...

13-Week Study to Evaluate the Safety and Efficacy of Oral VK2735 Dosed Once Daily SAN DIEGO, Jan. 8, 2025 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage ...

Viking held cash, cash equivalents and short-term investments of $903M, compared to $362M as of December 31, 2023. 2024 ...

Stephanie Diaz; Investor Relations Manager; Viking Therapeutics Inc. Brian Lian; President, Chief Executive Officer, Director; Viking Therapeutics Inc. Greg Zante; C ...